TI
Therapeutic Areas
Chugai Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Hemlibra (emicizumab) | Hemophilia A | Approved |
| Tecentriq (atezolizumab) | Multiple Cancers | Approved |
| Kadcyla (T-DM1) | HER2+ Breast Cancer | Approved |
| Phesgo | HER2+ Breast Cancer | Approved |
| Herceptin (trastuzumab) | HER2+ Cancers | Approved |
| Avastin (bevacizumab) | Multiple Cancers | Approved |
| Actemra (tocilizumab) | Rheumatoid Arthritis | Approved |
| Satralizumab | Neuromyelitis Optica | Approved |
Leadership Team at Chugai Pharmaceutical
OO
Osamu Okuda
President & CEO
TK
Tatsuro Kosaka
Executive Vice President & CFO
YT
Yutaka Tanaka
Senior Vice President, Head of Project & Lifecycle Management Unit
TY
Takahiro Yamauchi
Senior Vice President, Head of Clinical Development Center